Sanna Wilson-Hulkki

Downs Road
Rode, ENG SM25PT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.

Journal: Current oncology (Toronto, Ont.)

Published: February 03, 2022

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.

Journal: JCO precision oncology

Published: August 06, 2020

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

Journal: Gut

Published: July 28, 2020

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 19, 2019

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 24, 2018

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Journal: Science (New York, N.Y.)

Published: July 04, 2017

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Journal: Scientific reports

Published: June 06, 2017

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Journal: JAMA oncology

Published: February 28, 2017

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 23, 2015

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 03, 2014

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

Journal: Journal of the National Cancer Institute

Published: June 25, 2014

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 25, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026